Biotech sponsors accounted for almost two thirds of FDA approvals in 2024 – a significant shift from the prior year, when big or mid-sized pharma names sat behind just over half of approvals. This “biotech boost” isn’t all driven by rare diseases, with several big disease areas receiving new entrants from smaller players.
In this eBook, we investigate why biotechs are going-it-alone and look at the modalities and therapy areas driving the shift. In our biotech FDA approvals analysis, we discuss:
- Key FDA biotech approvals in 2024
- Whether the biotech dream of taking drugs to patients alone will hit the buffers of commercial reality
- The modalities where biotechs are thriving
- The biotechs to watch as their new drugs progress through the pipeline.
